Key result
Dysregulated membrane proteins may play a crucial role in the pathogenesis of joint hypermobility syndrome, contributing to musculoskeletal pain and other clinical manifestations.
Why the study?
Recent studies suggest membrane proteins may play a role in the pathogenesis of joint hypermobility syndrome, prompting an exploration of causative factors contributing to musculoskeletal pain and the syndrome's clinical aspects.
This review explores the pathogenesis, clinical manifestations, and management of Joint Hypermobility Syndrome, highlighting a potential role for dysregulated membrane proteins.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for membrane protein roles in JHS; should not yet change clinical practice.
Ehlers-Danlos syndromes (EDSs) constitute a heterogeneous group of connective tissue disorders characterized by joint hypermobility, skin hyperextensibility, and tissue fragility. Asymptomatic EDSs, joint hypermobility without associated syndromes, EDSs, and hypermobility spectrum disorders are the commonest phenotypes associated with joint hypermobility. Joint hypermobility syndrome (JHS) is a connective tissue disorder characterized by extreme flexibility of the joints, along with pain and other symptoms. JHS can be a sign of a more serious underlying genetic condition, such as EDS, which affects the cartilage, bone, fat, and blood. The exact cause of JHS could be related to genetic changes in the proteins that add flexibility and strength to the joints, ligaments, and tendons, such as collagen. Membrane proteins are a class of proteins embedded in the cell membrane and play a crucial role in cell signaling, transport, and adhesion. Dysregulated membrane proteins have been implicated in a variety of diseases, including cancer, cardiovascular disease, and neurological disorders; recent studies have suggested that membrane proteins may also play a role in the pathogenesis of JHS. This article presents an exploration of the causative factors contributing to musculoskeletal pain in individuals with hypermobility, based on research findings. It aims to provide an understanding of JHS and its association with membrane proteins, addressing the clinical manifestations, pathogenesis, diagnosis, and management of JHS.
No takes yet. Share an insight, caveat, or question.
Pliego-Arreaga et al. (2024) conducted a review in Joint Hypermobility Syndrome. Membrane proteins was evaluated. Dysregulated membrane proteins may play a crucial role in the pathogenesis of joint hypermobility syndrome, contributing to musculoskeletal pain and other clinical manifestations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: